Sein métastatique RH+
AIPAC
AIPAC (Active Immunotherapy PAClitaxel): A Multicentre, Phase IIb, Randomised,Double Blind, Placebo-controlled Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients Receiving IMP321 (LAG-3Ig Fusion Protein) or Placebo as Adjunctive to a Standard Chemotherapy Treatment Regimen of Paclitaxel
Saint-Cloud
ETIENNE BRAIN
Sein métastatique RH+
AMBRE
OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE III STUDY, COMPARING;STANDARD CHEMOTHERAPY TO ENDOCRINE THERAPY + ABEMACICLIB;COMBINATION AS INITIAL METASTATIC TREATMENT AMONG PATIENTS WITH;VISCERAL METASTASIS OF ER+ HER2- BREAST CANCER, HIGH BURDEN;DISEASE
Paris, Saint-Cloud
FRANCOIS-CLEMENT BIDARD, FRANCOIS-CLEMENT BIDARD
Gynécologie - Ovaires
ANITA
A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months
Paris, Saint-Cloud
MANUEL RODRIGUES, MANUEL RODRIGUES
Recherches "plusieurs pathologies"
ARIANES
A multicenter, open label, phase II basket trial exploring the efficacy and safety of the combination of rucaparib (PARP inhibitor) and atezolizumab (anti-PD-L1 antibody) in patients with DNA repair-deficient or platinum-sensitive solid tumors
Paris
FRANCESCO RICCI
Sarcomes
BFR ESS 01
Randomized Comparative Prospective Multicentre Phase II Trial Evaluating Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic LGESS
Paris
SOPHIE PIPERNO-NEUMANN, SOPHIE PIPERNO-NEUMANN
Sein métastatique RH+
BYLieve (CBYL719X402)
A Phase II, Multicenter, Open-label, Two-cohort, Non-comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After CDK 4/6 Inhibitor Treatment
Saint-Cloud
FLORENCE LEREBOURS
Sein métastatique RH+
CONTESSA - ODO-TE-B301
Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Saint-Cloud
ETIENNE BRAIN